ArticleFrontiers in oncology2026
Cancer screening utilization among insured beneficiaries in Saudi Arabia, 2023-2024: a national analysis of trends, calendar variation, and distribution across breast, cervical, and colorectal screening programs.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast, cervical, and colorectal cancer (CRC) screening uptake in Saudi Arabia has been reported as consistently low, but no national longitudinal description of insurance-linked screening utilization has been published. This study examined temporal trends, calendar variation, and demographic distribution of cancer screening among privately insured beneficiaries in Saudi Arabia. Methods: We analyzed six publicly available Council of Health Insurance datasets reporting monthly breast, cervical, and colorectal cancer screening counts among insured beneficiaries during 2023-2024 (24 monthly observations per cancer type). Because the datasets contain aggregate counts without enrollment or eligibility denominators, only absolute utilization counts could be analyzed. Two log-linear regression models were fitted to each monthly series: an unadjusted time-trend model and a primary adjusted model incorporating Ramadan and an October-December 2024 step-change term. Sensitivity analyses evaluated three alternative Ramadan exposure definitions. Results: Total screening counts increased by 56.3%, from 102,048 in 2023 to 159,496 in 2024. In the adjusted model, statistically significant upward monthly trends were observed for breast (+3.0%; 95% CI 1.5-4.5), cervical (+2.7%; 95% CI 1.6-3.8), and CRC screening (+4.6%; 95% CI 3.3-5.9) (all Conclusions: Insurance-linked cancer screening utilization increased substantially across all three screening programs between 2023 and 2024. A reproducible Ramadan-Eid-associated decline and a CRC-specific late-2024 increase were identified, providing insights relevant to screening program planning and evaluation. Because eligible-population denominators were unavailable, these findings describe utilization counts rather than screening participation or coverage and highlight the need for denominator linkage to enable future assessment of coverage and equity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.